Epirubicin
Refractory Nodal Marginal Zone Lymphoma
Mayo ClinicPhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Refractory Nodal Marginal Zone Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Mayo Clinic | Phase 2 | B |
Carfilzomib Mayo Clinic | Phase 1 | CC |
DARATUMUMAB Mayo Clinic | Phase 1 | CC |
FLUDEOXYGLUCOSE Mayo Clinic | Phase 1 | CC |
TRASTUZUMAB Mayo Clinic | Phase 1 | CC |
Nivolumab Mayo Clinic | Phase 1 | CC |
Copanlisib Mayo Clinic | Phase 1 | CC |
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →